Literature DB >> 23225854

Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations.

Jing-yi Zhao1, Yang Lu, Shou-ying Du, Xiao Song, Jie Bai, Yue Wang.   

Abstract

Borneol, a monoterpenoid alcohol, is used widely, particularly in combined formulas for preventing and curing cardiovascular and cerebrovascular diseases in traditional Chinese medicine. In order to understand the blood and brain pharmacokinetics after intravenous, intranasal, or oral administration and to investigate the superiority and feasibility of intranasal administration, a simple gas chromatographic (GC) method with flame ionization detection (FID) was developed for the quantification of borneol. Blood samples and brain were collected from mice at 1, 3, 5, 10, 20, 30, 60, 90, and 120 min after intravenous, intranasal, or oral administration of borneol at a dosage of 30.0 mg/kg. Sample preparations were carried out by liquid-liquid extraction with an internal standard solution of octadecane. The pharmacokinetic parameters were calculated by the software of Kinetica. The calibration curves were linear in the range of 0.11-84.24 μg/ml and 0.16-63.18 μg/g for borneol in plasma and brain, respectively. The methodological and extraction recoveries were both in the range of 85%-115%. The intra-day and inter-day variabilities for plasma and brain samples were ≤5.00% relative standard deviation (RSD). The absolute bioavailabilities F of intranasal and oral administrations were 90.68% and 42.99%. The relative brain targeted coefficients Re of intranasal and oral administrations were 68.37% and 38.40%. The GC-FID method developed could be applied to determination and pharmacokinetic study. The borneol from injection was distributed and metabolized fast without absorption process. The borneol from oral administration was distributed more slowly and had the lowest absolute bioavailability. Nasal administration of borneol was quickly absorbed into the blood and brain, was easy to use and had a greater safety than infection, which makes it worthy of further development as an administration route for encephalopathy treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23225854      PMCID: PMC3520453          DOI: 10.1631/jzus.B1200142

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  19 in total

1.  Sniffing neuropeptides: a transnasal approach to the human brain.

Authors:  Jan Born; Tanja Lange; Werner Kern; Gerard P McGregor; Ulrich Bickel; Horst L Fehm
Journal:  Nat Neurosci       Date:  2002-06       Impact factor: 24.884

Review 2.  Intranasal delivery of biologics to the central nervous system.

Authors:  Jeffrey J Lochhead; Robert G Thorne
Journal:  Adv Drug Deliv Rev       Date:  2011-11-15       Impact factor: 15.470

Review 3.  Intranasal delivery: physicochemical and therapeutic aspects.

Authors:  Henry R Costantino; Lisbeth Illum; Gordon Brandt; Paul H Johnson; Steven C Quay
Journal:  Int J Pharm       Date:  2007-03-25       Impact factor: 5.875

4.  Delivery of 125I-cobrotoxin after intranasal administration to the brain: a microdialysis study in freely moving rats.

Authors:  Fanzhu Li; Jian Feng; Qiaoyuan Cheng; Wenjing Zhu; Yuji Jin
Journal:  Int J Pharm       Date:  2006-08-18       Impact factor: 5.875

5.  Effect of borneol on the distribution of gastrodin to the brain in mice via oral administration.

Authors:  Zheng Cai; Shixiang Hou; Yuanbo Li; Binbin Zhao; Zhaoxiang Yang; Shuguang Xu; Junxue Pu
Journal:  J Drug Target       Date:  2008-02       Impact factor: 5.121

6.  Influence of borneol on primary mice oral fibroblasts: a penetration enhancer may be used in oral submucous fibrosis.

Authors:  Jian-Ping Dai; Jun Chen; Yu-Fei Bei; Bang-Xing Han; Sheng Wang
Journal:  J Oral Pathol Med       Date:  2009-03       Impact factor: 4.253

7.  Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system.

Authors:  Shyeilla V Dhuria; Leah R Hanson; William H Frey
Journal:  J Pharmacol Exp Ther       Date:  2008-10-22       Impact factor: 4.030

8.  Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.

Authors:  Leah R Hanson; Annina Roeytenberg; Paula M Martinez; Valerie G Coppes; Donald C Sweet; Reshma J Rao; Dianne L Marti; John D Hoekman; Rachel B Matthews; William H Frey; S Scott Panter
Journal:  J Pharmacol Exp Ther       Date:  2009-06-09       Impact factor: 4.030

9.  Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits.

Authors:  Ahmed H Elshafeey; Ehab R Bendas; Osama H Mohamed
Journal:  AAPS PharmSciTech       Date:  2009-03-31       Impact factor: 3.246

Review 10.  Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.

Authors:  Leah R Hanson; William H Frey
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more
  7 in total

1.  Comparative pharmacokinetics of borneol in cerebral ischemia-reperfusion and sham-operated rats.

Authors:  Pan Xu; Ying Li; Shou-ying Du; Yang Lu; Jie Bai; Qing-li Guo
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

2.  Sensitive assay for measurement of volatile borneol, isoborneol, and the metabolite camphor in rat pharmacokinetic study of Borneolum (Bingpian) and Borneolum syntheticum (synthetic Bingpian).

Authors:  Chen Cheng; Xin-Wei Liu; Fei-Fei Du; Mei-Juan Li; Fang Xu; Feng-Qing Wang; Yang Liu; Chuan Li; Yan Sun
Journal:  Acta Pharmacol Sin       Date:  2013-08-26       Impact factor: 6.150

3.  Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood-brain barrier permeability.

Authors:  Qun-Lin Zhang; Bingmei M Fu; Zhang-Jin Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Pre-treatment with a Xingnaojing preparation ameliorates sevoflurane-induced neuroapoptosis in the infant rat striatum.

Authors:  Zhou-Jing Yang; Ying-Wei Wang; Chang-Lin Li; Li-Qing Ma; Xuan Zhao
Journal:  Mol Med Rep       Date:  2014-11-13       Impact factor: 2.952

Review 5.  Storax, A Promising Botanical Medicine for Treating Cardio-Cerebrovascular Diseases: A Review.

Authors:  Zhuo Xu; Danni Lu; Jianmei Yuan; Mihong Ren; Rong Ma; Qian Xie; Yong Li; Jinxiu Li; Jian Wang
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

Review 6.  Potential clinical applications of phytopharmaceuticals for the in-patient management of coagulopathies in COVID-19.

Authors:  Ashis K Mukherjee; Dhruba J Chattopadhyay
Journal:  Phytother Res       Date:  2022-02-11       Impact factor: 6.388

7.  TRPM8-regulated calcium mobilization plays a critical role in synergistic chemosensitization of Borneol on Doxorubicin.

Authors:  Haoqiang Lai; Chang Liu; Liyuan Hou; Wenwei Lin; Tianfeng Chen; An Hong
Journal:  Theranostics       Date:  2020-08-13       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.